Latest Headlines

41. Novaliq Receives FDA IND Clearance To Advance NOV05 In A Phase II Clinical Trial In Non-Infectious Anterior Uveitis 1/26/2026

    Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol drug category, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NOV05, the company’s first IND for treating inner-eye diseases.

42. New Platform To Accelerate Cardiac Drug Development 1/22/2026

    Researchers from Leiden University Medical Center (LUMC) and the Leiden-based biotech company Ncardia have joined forces to develop a new platform that enables the automated production of 3D cardiac microtissues.

43. Ellipses In-Licenses First-In-Class B7H3 Antibody Drug Conjugate From China 1/22/2026

    Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative programmes, announced that it has entered into a collaboration and licence agreement with Innolake Biopharm Co. Ltd (“Innolake”) to develop a clinical stage first-in-class antibody drug conjugate (ADC).

44. Voyager Enables Microgravity-Enabled Drug Discovery 1/22/2026

    Voyager Technologies announced a new contract with Space LiinTech to manifest a new payload to the International Space Station, advancing microgravity-enabled drug discovery.

45. FluoGuide Submits An IND For FG001, To Initiate First U.S. Registration Trial 1/21/2026

    FluoGuide A/S (“FluoGuide” or the “Company”), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for FG001.

46. Vanderbilt Institute For Therapeutic Advances Launches To Redefine Drug Discovery And Biomedical Innovation 1/21/2026

    Vanderbilt University has announced the Vanderbilt Institute for Therapeutic Advances as part of its bold Discovery Vanderbilt initiative, establishing a pioneering hub to catalyze next-generation breakthroughs in therapeutic discovery.

47. Opna Bio Announces Orphan Drug Designation Granted To OPN-2853 (Zavabresib) For The Treatment Of Myelofibrosis 1/21/2026

    Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, today announced that OPN-2853, a bromodomain and extra-terminal motif (BET) small molecule inhibitor, has been granted Orphan Drug Designation (ODD) for the treatment of myelofibrosis (MF) by the U.S. Food and Drug Administration (FDA).

48. FAR Biotech Officially Establishes Wisconsin Presence, Expanding Its QuantumAI Drug Discovery Programs In Madison 1/21/2026

    FAR Biotech, a computational drug discovery company using proprietary quantum modeling and deep learning AI to tackle high impact diseases with significant unmet medical need, today announced that it has officially moved to Wisconsin.

49. Chinese NMPA Accepts New Drug Application For Illuccix For Prostate Cancer Imaging 1/20/2026

    Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (NDA) for TLX591-Px (Illuccix®, Kit for the preparation of 68Ga-PSMA-11), Telix's lead prostate cancer imaging agent.

50. Rein Therapeutics Receives Orphan Drug Designation From European Medicines Agency For Lead Drug Candidate In Idiopathic Pulmonary Fibrosis 1/20/2026

    Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that it has received orphan drug designation from the European Medicines Agency (EMA) for LTI-03, its lead drug candidate aimed at preserving lung function in patients with idiopathic pulmonary fibrosis (IPF).